gemcitabine and cisplatin

Phase 3Small molecule

gemcitabine and cisplatin is one of 100 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaCompleted

Unresectable Biliary Tract CarcinomaRecruiting

Bladder CancerCompleted

Nasopharyngeal CarcinomaPhase 3

Completed

Unresectable Biliary Tract CarcinomaPhase 2

Recruiting

Bladder CancerPhase 3

Completed

Competition

Competitive Landscape

118 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

52 2

Keytruda

Merck & Co.

Phase 3

27 3

Opdivo

Bristol-Myers Squibb

Phase 3

20 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

57 5

Tecentriq

Roche

Phase 3

16 6

Imfinzi

AstraZeneca

Phase 3

16 7

Trexall

Jazz Pharmaceuticals

Phase 3

12 8

Padcev

Pfizer

Phase 3

8 9

Imjudo

AstraZeneca

Phase 3

8 10

Gemzar

GGynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Bladder Cancer

NCT05531123

Q2 2027

Phase 2Recruiting

Unresectable Biliary Tract Carcinoma

NCT06749730

Q3 2027

Phase 2Not yet recruiting

Bladder Cancer

NCT07184021

Q4 2027

Phase 3Recruiting

Cholangiocarcinoma

NCT05823311

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma8 trials

GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Completed·—·Phase 2·NCT01596868·60 enrolled

Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT01915134·362 enrolled

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT03840421·468 enrolled

Show 5 more trials

Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma

Completed·SSun Yat-sen University·Phase 3·NCT01528618·362 enrolled

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Unknown status·SSun Yat-sen University·Phase 1·NCT04073784·41 enrolled

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·N/A·NCT02627807·386 enrolled

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT01872962·480 enrolled

Concurrent Chemoradiotherapy Alone Versus Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Low-risk Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05979961·464 enrolled

Bladder Cancer4 trials

Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

Completed·—·Phase 3·NCT01734798·198 enrolled

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01589094·51 enrolled

Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

Not yet recruiting·—·Phase 2·NCT07184021·30 enrolled

Show 1 more trial

A Prospective Phase II Study of Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer After Chemotherapy Combined With PD-1 Antibody(Rebirth)

Active, not recruiting·FFudan University·Phase 2·NCT05531123·30 enrolled

Cholangiocarcinoma3 trials

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

Terminated·EEpicentRx, Inc.·Phase 2·NCT02452970·4 enrolled

Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05823311·80 enrolled

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05532059·100 enrolled

Pancreatic Cancer2 trials

Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer

Completed·SSeoul National University Hospital·Phase 2·NCT01396681·70 enrolled

Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05182112·1 enrolled

Combination Therapy1 trial

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Completed·FFudan University·Phase 2·NCT00601159·70 enrolled

9 more indications

Stereotactic Body Radiotherapy1 trial

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06349044·120 enrolled

Unresectable Biliary Tract Carcinoma1 trial

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06749730·63 enrolled

Cervical Cancer1 trial

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

Unknown status·CChuangzhen Chen·Phase 3·NCT05189028·290 enrolled

Advanced Solid Tumors1 trial

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Unknown status·HHutchison Medipharma Limited·Phase 1/2·NCT05173142·141 enrolled

Concurrent Chemoradiotherapy1 trial

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

Unknown status·CChaosu Hu·Phase 3·NCT03366415·420 enrolled

Glioma1 trial

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Completed·FForma Therapeutics, Inc.·Phase 1/2·NCT03684811·93 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer

Withdrawn·LLahey Clinic·Phase 2·NCT00696007

Chemotherapy1 trial

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Unknown status·SShi Ming·Phase 3·NCT04961970·188 enrolled

Urothelial Carcinoma1 trial

Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01261728·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for gemcitabine and cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine and cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine and cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forma Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForma Therapeutics, Inc.

gemcitabine and cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Nasopharyngeal Carcinoma8 trials

Bladder Cancer4 trials

Cholangiocarcinoma3 trials

Pancreatic Cancer2 trials

Combination Therapy1 trial

Stereotactic Body Radiotherapy1 trial

Unresectable Biliary Tract Carcinoma1 trial

Cervical Cancer1 trial

Advanced Solid Tumors1 trial

Concurrent Chemoradiotherapy1 trial

Glioma1 trial

Neoadjuvant Chemotherapy1 trial

Chemotherapy1 trial

Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News